In this featured interview on KRON-TV San Francisco, Dotmatics VP of Science & Technology, Phil Mounteney, shares how artificial intelligence is transforming drug discovery and development. He explains how AI today serves as a “research assistant,” automating data-heavy tasks and accelerating analysis, but in the near future will act as a true research partner by helping predict new drug targets, design molecules, and enable more personalized therapies.
Phil also highlights why speed matters in healthcare, how AI can significantly reduce the cost and time to bring drugs to market, and how these advances will expand access to safer, more tailored medicines for patients worldwide.
Watch the full interview to discover how Dotmatics is helping researchers harness AI to accelerate breakthroughs and shape the future of medicine.
Learn More About Dotmatics
Schedule a meeting with our team to learn more about Luma's AI capabilities.